| Title |
The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials
|
|---|---|
| Published in |
Targeted Oncology, January 2013
|
| DOI | 10.1007/s11523-013-0257-x |
| Pubmed ID | |
| Authors |
F. Petrelli, K. Borgonovo, S. Barni |
| Abstract |
Skin rash is an early and frequent phenomenon during treatment with anti-epidermal growth factor receptor monoclonal antibodies. The objective of this review is to assess the predictive value of skin rash in patients with advanced colorectal cancer treated with cetuximab and panitumumab. We searched PubMed and ASCO Meetings for publications reporting the correlation of skin rash with survival and/or response rate. Hazard ratios (HRs) with 95% confidence intervals for progression and/or survival, and/or risk ratios (RRs) for response rate in patients with rash were obtained from publications and pooled in a meta-analysis. Fourteen publications (for a total of 3,833 patients) were included in this meta-analysis. The occurrence of skin toxicity represents a predictive factor for survival (HR 0.51; p<0.00001) and progression (HR 0.58; p<0.00001). Similarly, patients who developed moderate or severe rash had an increased chance of response (35 vs 13%; RR 2.23, p<0.00001). The occurrence of skin rash during treatment with cetuximab and panitumumab represents a significant predictor of the efficacy of these drugs. The hypothesis that, in patients who lack substantial skin toxicity, this treatment is not beneficial and requires early discontinuation deserves further study. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 66 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Indonesia | 1 | 2% |
| Chile | 1 | 2% |
| Ecuador | 1 | 2% |
| Brazil | 1 | 2% |
| Estonia | 1 | 2% |
| Unknown | 61 | 92% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 13 | 20% |
| Student > Ph. D. Student | 10 | 15% |
| Other | 6 | 9% |
| Student > Postgraduate | 6 | 9% |
| Student > Master | 5 | 8% |
| Other | 15 | 23% |
| Unknown | 11 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 31 | 47% |
| Agricultural and Biological Sciences | 7 | 11% |
| Biochemistry, Genetics and Molecular Biology | 3 | 5% |
| Engineering | 3 | 5% |
| Immunology and Microbiology | 2 | 3% |
| Other | 7 | 11% |
| Unknown | 13 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 June 2014.
All research outputs
#19,490,402
of 24,823,556 outputs
Outputs from Targeted Oncology
#358
of 602 outputs
Outputs of similar age
#225,611
of 296,585 outputs
Outputs of similar age from Targeted Oncology
#6
of 13 outputs
Altmetric has tracked 24,823,556 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 602 research outputs from this source. They receive a mean Attention Score of 3.5. This one is in the 29th percentile – i.e., 29% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 296,585 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 21st percentile – i.e., 21% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 53% of its contemporaries.